NCT01152866View on ClinicalTrials.gov

An Open Label, Canadian Phase IIIb Study With Ovidrel in Ovulation Induction (OI) and Assisted Reproductive Technique (ART)

CompletedOBSERVATIONAL
Enrollment

3

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

December 31, 2004

Study Completion Date

December 31, 2004

Conditions
Ovulation InductionInfertility
Interventions
DRUG

Choriogonadotropin alpha (r-hCG)

Choriogonadotropin alpha 250 μg was administered subcutaneously on the day following the last dose of follitropin alpha (Gonal-F).

Sponsors

Lead Sponsor

EMD Serono
All Listed Sponsors
lead

EMD Serono

INDUSTRY

NCT01152866 - An Open Label, Canadian Phase IIIb Study With Ovidrel in Ovulation Induction (OI) and Assisted Reproductive Technique (ART) | Biotech Hunter | Biotech Hunter